Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 3/20 | 0.63 |
| ▸ | GPR35 | Q9HC97 | 2/20 | 0.63 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.59 |
| ▸ | HPGD | P15428 | 3/20 | 0.53 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.53 |
| ▸ | LDHA | P00338 | 1/20 | 0.53 |
| ▸ | THRB | P10828 | 1/20 | 0.53 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.53 |
| ▸ | TSHR | P16473 | 1/20 | 0.53 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.53 |
| ▸ | ATIC | P31939 | 1/20 | 0.53 |
| ▸ | ME2 | P23368 | 1/20 | 0.52 |
| ▸ | ME1 | P48163 | 1/20 | 0.52 |
| ▸ | ME3 | Q16798 | 1/20 | 0.52 |
| ▸ | MEN1 | O00255 | 6/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.50 |
| ▸ | MAPT | P10636 | 3/20 | 0.50 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3391301 | 0.83 | POLB (0.69) | POLBGPR35CYP2D6HPGDHSD17B10 | |
| SCHEMBL569862 | 0.82 | GRIN2D (0.69) | POLBGPR35CYP2D6HPGDHSD17B10 | |
| SCHEMBL989695 | 0.81 | POLB (0.67) | POLBGPR35CYP2D6HPGDHSD17B10 | |
| SCHEMBL9250480 | 0.81 | GRIN2D (0.44) | POLBGPR35CYP2D6HPGDHSD17B10 | |
| SCHEMBL5380957 | 0.80 | ME2 (0.70) | POLBGPR35CYP2D6HPGDHSD17B10 | |
| SCHEMBL27377431 | 0.79 | GPR35 (0.47) | POLBGPR35CYP2D6HPGDHSD17B10 | |
| SCHEMBL30943793 | 0.79 | GRIN2D (0.69) | POLBGPR35CYP2D6HPGDHSD17B10 | |
| SCHEMBL1224667 | 0.79 | POLB (0.63) | POLBGPR35CYP2D6HPGDHSD17B10 | |
| SCHEMBL3925192 | 0.79 | POLB (0.63) | POLBGPR35CYP2D6HPGDHSD17B10 | |
| SCHEMBL6826456 | 0.79 | POLB (0.63) | POLBGPR35CYP2D6HPGDHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 58 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025018169-A1 | RESIST COMPOSITION, RESIST PATTERN FORMATION METHOD, COMPOUND, AND POLYMER COMPOUND | 東京応化工業株式会社 | 2025-01-23 | — | — | WO | disclosed |
| WO-2012019106-A2 | POSITIVE AND NEGATIVE MODULATORS OF NMDA RECEPTORS | BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA (US) | 2012-02-09 | — | — | WO | disclosed |
| US-7879893-B2 | Zinc binding ligand; sustained release of insulin | NOVO NORDISK A/S (DK) | 2011-02-01 | — | — | US | disclosed |
| US-7879893-B2 | Zinc binding ligand; sustained release of insulin | NOVO NORDISK A/S (DK) | 2011-02-01 | — | — | US | disclosed |
| US-7879893-B2 | Zinc binding ligand; sustained release of insulin | NOVO NORDISK A/S (DK) | 2011-02-01 | — | — | US | disclosed |
| US-20090123563-A1 | Pharmaceutical Preparations Comprising Insulin, Zinc Ions and Zinc-Binding Ligand | NOVO NORDISK A/S (DK) | 2009-05-14 | — | — | US | disclosed |
| US-20090123563-A1 | Pharmaceutical Preparations Comprising Insulin, Zinc Ions and Zinc-Binding Ligand | NOVO NORDISK A/S (DK) | 2009-05-14 | — | — | US | disclosed |
| US-20090123563-A1 | Pharmaceutical Preparations Comprising Insulin, Zinc Ions and Zinc-Binding Ligand | NOVO NORDISK A/S (DK) | 2009-05-14 | — | — | US | disclosed |
| EP-1585541-B1 | PHARMACEUTICAL COMPOSITIONS COMPRISING INSULIN AND LEGENDS OF INSULIN HEXAMER | NOVO NORDISK AS (DK) | 2007-11-14 | — | — | EP | disclosed |
| EP-1429763-B1 | NOVEL LIGANDS FOR THE HisB10 Zn2+ SITES OF THE R-STATE INSULIN HEXAMER | NOVO NORDISK AS (DK) | 2007-05-30 | — | — | EP | disclosed |
| WO-2002012168-A1 | NOVEL N-(2-PHENYL-3-AMINOPROPYL)NAPHTAMIDES | ASTRAZENECA AB (SE) | 2002-02-14 | — | — | WO | disclosed |
| EP-1169302-A1 | N-(2-PHENYL-4-AMINO-BUTYL)-1-NAPHTHAMIDES AS NEUROKININ-1 RECEPTOR ANTAGONISTS | AstraZeneca AB (SE) | 2002-01-09 | — | — | EP | disclosed |
| CN-1322196-A | Naphthalenecarboxamides as tachykinin receptor antagonists | ASTRA ZENECA N N (SE) | 2001-11-14 | — | — | CN | disclosed |
| CN-1322134-A | Naphthalenecarboxamides as tachykinin receptor antagonists | ASTRA ZENECA N V (SE) | 2001-11-14 | — | — | CN | disclosed |
| WO-2001077069-A1 | NAPHTHAMIDE NEUROKININ ANTAGONISTS FOR USE AS MEDICAMENTS | ASTRAZENECA AB (SE) | 2001-10-18 | — | — | WO | disclosed |
| EP-1119551-A1 | NAPHTHALENECARBOXAMIDES AS TACHYKININ RECEPTOR ANTAGONISTS | AstraZeneca AB (SE) | 2001-08-01 | — | — | EP | disclosed |
| EP-1119355-A1 | NAPHTHALENECARBOXAMIDES AS TACHYKININ RECEPTOR ANTAGONISTS | AstraZeneca AB (SE) | 2001-08-01 | — | — | EP | disclosed |
| WO-2000059873-A1 | N-(2-PHENYL-4-AMINO-BUTYL)-1-NAPHTHAMIDES AS NEUROKININ-1 RECEPTOR ANTAGONISTS | ASTRAZENECA AB (SE) | 2000-10-12 | — | — | WO | disclosed |
| WO-2000020003-A1 | NAPHTHALENECARBOXAMIDES AS TACHYKININ RECEPTOR ANTAGONISTS | ASTRAZENECA AB (SE) | 2000-04-13 | — | — | WO | disclosed |
| WO-2000020389-A1 | NAPHTHALENECARBOXAMIDES AS TACHYKININ RECEPTOR ANTAGONISTS | ASTRAZENECA AB (SE) | 2000-04-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090123563-A1 | Pharmaceutical Preparations Comprising Insulin, Zinc Ions and Zinc-Binding Ligand | IAPP, IRS1, HBB | POLB 2360/4885GPR35 804/4885CYP2D6 3190/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.